专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050048039A1 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues 审中-公开
标题翻译：用扩散或难以接近细胞或组织治疗或诊断人类病理的方法
公开(公告)号：US20050048039A1
公开(公告)日：2005-03-03
申请号：US10766929
申请日：2004-01-30
申请人： Patrick Dreyfus , Elaine Parrish , Luis Garcia , Mohamed Chokri , Jacques Bartholeyns , Elise Peltekian
发明人： Patrick Dreyfus , Elaine Parrish , Luis Garcia , Mohamed Chokri , Jacques Bartholeyns , Elise Peltekian
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K48/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P19/08 , A61P21/00 , A61P25/00 , A61P25/02 , C12N5/0786 , C12N5/10 , G01N33/569 , G01N33/68
CPC分类号： C12N5/0645 , A61K38/00 , A61K48/00 , C12N2510/00 , G01N33/56972 , G01N33/6893 , G01N33/6896
摘要： Method for the treatment or diagnosis of pathologies either expressed in injured or pathological multiple sites in tissues or in the body or expressed in injured or pathological sites of tissues or cells in sites of the body, which are difficult to access, with said sites or areas in immediate proximity to said sites being the source of the release of chemotactic factors for endogenous macrophages, either spontaneously or upon suitable stimulation, wherein said treatment is carried out by administration to the body of an appropriate amount of exogenous monocyte derived cells, said monocyte derived cells being, in the case of treatment, loaded with corrective agents with respect to the pathologies to be treated, and with said monocyte derived cells having the properties of mobilisation towards the source of the above-said released chemotactic factors and in target the cells present in the vicinity of the said released chemotactic factors, and in the case of diagnosis, loaded with a marker enabling the detection of injured or pathological sites.
摘要翻译：用于治疗或诊断在组织或体内的损伤或病理多个部位中表达的病理学或在身体部位的组织或细胞的损伤或病理部位表达的病症，所述部位或部位难以进入所述部位或区域紧邻所述位点是内源性巨噬细胞的趋化因子释放的来源，或者是自发地或在适当的刺激下，其中所述的治疗通过向人体施用适量的外源性单核细胞来源的细胞来进行，所述单核细胞来源于在治疗的情况下，细胞相对于待治疗的病理物质加载校正剂，并且所述单核细胞衍生的细胞具有向上述释放的趋化因子的来源移动的性质，并且靶向存在的细胞在所述释放的趋化因子附近，并且在诊断的情况下装载标记呃能够检测受伤或病理部位。

2. 发明申请

US20030108534A1 Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 审中-公开
标题翻译：巨噬细胞，其制备方法及其作为药物组合物的活性物质的用途
公开(公告)号：US20030108534A1
公开(公告)日：2003-06-12
申请号：US10336726
申请日：2003-01-06
申请人： I.D.M. Immuno-Designed Molecules
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K048/00 , A61K038/21 , C12N005/08
CPC分类号： C12N5/0645 , A61K2035/124 , C12N2500/38 , C12N2501/22 , C12N2501/24 , Y10S435/81
摘要： The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-null is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-null is increased by about 20 to 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-null is in a ratio such that after 60 h of activation with IFN-null, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-null activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.
摘要翻译：本发明涉及具有以下性质中的至少一种的巨噬细胞：相对于标准巨噬细胞，其IFN-γ的细胞毒活性增加约20至30％，优选为约70％; 它们与IFN-γ的细胞毒活性相对于标准巨噬细胞增加约20至40％，优选为约93％; 响应于IFN-γ的激活，细胞毒活性的失活的延长使得在IFN-γ活化60小时后，细胞毒活性高于或等于30％，优选约55 与由于IFN-γ活化引起的巨噬细胞呈现的最大细胞毒活性相比，所述细胞毒活性被测量为目标肿瘤细胞，特别是U 937细胞的3-H胸苷掺入的抑制百分比。

3. 发明授权

US6051432A Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 失效
标题翻译：巨噬细胞，其制备方法及其作为药物组合物的活性物质的用途
公开(公告)号：US6051432A
公开(公告)日：2000-04-18
申请号：US400875
申请日：1999-09-22
申请人： Mohamed Chokri , Jacques Bartholeyns
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K35/12 , C12N5/0786 , C12Q1/00 , G01N33/53
CPC分类号： C12N5/0645 , A61K2035/124 , C12N2500/38 , C12N2501/22 , C12N2501/24 , Y10S435/81
摘要： The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.
摘要翻译：本发明涉及具有以下性质中的至少一种的巨噬细胞：其相对于标准巨噬细胞而言，其IFN-γ的细胞毒性活性增加约20％至30％，优选为约70％; 其与IFN-γ的细胞毒活性相对于标准巨噬细胞增加约20至约40％，优选为约93％; 与IFN-γ的激活相应的细胞毒活性的失活的延长使得在用IFN-γ活化60小时后，细胞毒活性高于或等于30％，优选约55 与由IFN-γ激活引起的巨噬细胞呈现的最大细胞毒活性相比，所述细胞毒活性被测量为目标肿瘤细胞尤其是U937细胞3-H胸苷掺入的抑制百分比。

4. 发明授权

US5662899A Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 失效
标题翻译：巨噬细胞，其制备方法及其作为药物组合物的活性物质的用途
公开(公告)号：US5662899A
公开(公告)日：1997-09-02
申请号：US374629
申请日：1995-01-17
申请人： Mohamed Chokri , Jacques Bartholeyns
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K35/12 , A61K35/15 , A61K35/17 , A61P35/00 , C07K16/46 , C12N5/0786 , C12P21/08 , C12N5/08 , A61K35/14 , A61K35/26 , A61K35/28
CPC分类号： A61K35/17 , A61K35/15 , C07K16/468 , C12N5/0645 , A61K2035/124 , C12N2500/38 , C12N2501/02 , C12N2501/22 , C12N2501/24
摘要： Macrophages have been developed, which possess at least one of the following properties:their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%;their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%;deactivation of the cytotoxic activity following activation of IFN-.gamma. is such that sixty hours after activation with IFN-.gamma., the residual cytotoxic activity is at least 30%, preferably about 55%, of the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells. The macrophages are prepared by culturing healthy human monocytes and lymphocytes in a culture medium containing 1,25-dihydroxy vitamin D.sub.3 and GM-CSF.
摘要翻译： PCT No.PCT / EP93 / 01232 Sec。 371日期1995年1月17日 102（e）日期1995年1月17日PCT提交1993年5月18日PCT公布。第WO94 / 26875号公报日期1994年11月24日已经开发了具有至少以下性质之一的巨噬细胞：相对于标准巨噬细胞，其IFN-γ的细胞毒性活性增加约20至30％，优选为约70％; 其与IFN-γ的细胞毒活性相对于标准巨噬细胞增加约20至约40％，优选为约93％; IFN-γ活化后细胞毒活性的失活使得用IFN-γ活化后的六十小时，剩余的细胞毒性活性是巨噬细胞由于IFN引起的最大细胞毒性活性的至少30％，优选约55％ - γ激活，所述细胞毒活性被测量为目标肿瘤细胞，特别是U 937细胞的3-H胸苷掺入的抑制百分比。通过在含有1,25-二羟基维生素D3和GM-CSF的培养基中培养健康的人单核细胞和淋巴细胞来制备巨噬细胞。

5. 发明申请

US20040018184A1 Combined preparation for the treatment of neoplasic diseases or of infectious diseases 审中-公开
公开(公告)号：US20040018184A1
公开(公告)日：2004-01-29
申请号：US10622727
申请日：2003-07-21
申请人： I.D.M. IMMUNO-DESIGNED MOLECULES
发明人： Jacques Bartholeyns , Yves Fouron , Jean-Loup Romet-Lemonne
IPC分类号： A61K048/00 , A61K031/715 , A61K031/7008 , A61K031/43 , A61K031/522
CPC分类号： C12N5/0645 , A61K31/232 , A61K31/282 , A61K31/336 , A61K31/407 , A61K31/505 , A61K31/655 , A61K31/704 , A61K35/15 , A61K39/0011 , A61K45/06 , A61K2039/5154 , A61K2300/00
摘要： The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.

6. 发明授权

US6140122A Process for preparing macrophages, kits, and compositions for the use of this process 失效
标题翻译：用于制备巨噬细胞，试剂盒和组合物以用于该方法的方法
公开(公告)号：US6140122A
公开(公告)日：2000-10-31
申请号：US25454
申请日：1998-02-18
申请人： Jean-Loup Romet-Lemonne , Mohamed Chokri
发明人： Jean-Loup Romet-Lemonne , Mohamed Chokri
IPC分类号： G01N33/53 , A61K35/12 , A61K35/14 , A61K35/15 , A61K39/00 , C12N5/0786 , C12N5/22 , C12N5/00
CPC分类号： A61K35/15 , C12N5/0645 , A61K2035/124 , A61K2039/5154 , C12N2500/38 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/25 , Y10S435/975
摘要： The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits for reducing this process to practice.
摘要翻译：本发明涉及一种制备包含巨噬细胞，任选活化的组合物和/或衍生自具有强抗原呈递潜力的单核细胞的细胞的组合物的方法，所述方法包括存在于起始组合物中的单核细胞培养阶段，该阶段为前和/或之后是除了存在于起始组合物中的单核细胞以外的所有或部分成分的全部或部分，借助于针对所述成分的抗体，和/或随后进行淘析阶段。本发明还涉及用于减少该实施方法的试剂盒的组合物。

7. 发明授权

US07252996B2 Ancillary composition for the preparation of committed mature dentritic cells 失效
标题翻译：用于制备成熟的树突状细胞的辅助组合物
公开(公告)号：US07252996B2
公开(公告)日：2007-08-07
申请号：US10466186
申请日：2001-12-29
申请人： Claire Boccaccio , Alessandra Nardin , Jean-Pierre Abastado
发明人： Claire Boccaccio , Alessandra Nardin , Jean-Pierre Abastado
IPC分类号： C12N5/02
CPC分类号： C12N5/0639 , A61K38/217 , A61K2039/5154 , A61K2039/55511 , C12N2500/72 , C12N2501/056 , C12N2501/22 , C12N2501/23 , C12N2501/24 , A61K35/74 , A61K2300/00
摘要： The invention consists in the use of a maturation agent comprising a mixture of ribosomal and/or membrane fractions for the preparation of mature dendritic cells from immature dendritic cells.
摘要翻译：本发明包括使用包含核糖体和/或膜部分的混合物的成熟剂来制备来自未成熟树突状细胞的成熟树状细胞。

8. 发明授权

US06881413B1 Humanized biomaterials, a process for their preparation and their applications 失效
标题翻译：人造生物材料，其制备过程及其应用
公开(公告)号：US06881413B1
公开(公告)日：2005-04-19
申请号：US10069575
申请日：2000-08-22
申请人： Jacques Bartholeyns
发明人： Jacques Bartholeyns
IPC分类号： A61L27/38 , A61L27/40 , C12N5/08 , A61K9/00 , A61F2/02
CPC分类号： A61L27/3813 , A61F2/28 , A61L27/12 , A61L27/38 , A61L27/3804 , A61L27/3843 , A61L27/3895 , A61L27/40 , A61L27/507 , A61L27/60
摘要： The invention relates to humanized biomaterial comprising a porous biocompatible composite material customized and implanted with monocyte derived cells preferably with macrophages.
摘要翻译：本发明涉及包含多孔生物相容性复合材料的人源化生物材料，所述多孔生物相容性复合材料定制并植入优选与巨噬细胞的单核细胞衍生细胞。

9. 发明授权

US6001351A Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 失效
公开(公告)号：US6001351A
公开(公告)日：1999-12-14
申请号：US896498
申请日：1997-07-18
申请人： Mohamed Chokri , Jacques Bartholeyns
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K35/12 , A61K35/14 , A61K35/15 , A61K35/17 , A61P35/00 , C07K16/46 , C12N5/0786 , A61K48/00 , C12N5/08 , C12N15/85
CPC分类号： C07K16/468 , A61K35/15 , A61K35/17 , C12N5/0645 , C12N2500/38 , C12N2501/02 , C12N2501/22 , C12N2501/24
摘要： The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.

10. 发明授权

US5595897A Polylysine conjugates 失效
标题翻译：聚赖氨酸共轭物
公开(公告)号：US5595897A
公开(公告)日：1997-01-21
申请号：US288681
申请日：1994-08-10
申请人： Patrick Midoux , Patrick Erbacher , Annie-Claude Roche-Degremont , Michel Monsigny
发明人： Patrick Midoux , Patrick Erbacher , Annie-Claude Roche-Degremont , Michel Monsigny
IPC分类号： A61K47/48 , C12N15/87 , C07K1/00 , C07K1/107 , C12N15/00 , C12N15/88
CPC分类号： C12N15/87 , A61K47/48315
摘要： The invention concerns a complex between at least one negatively charged nucleic acid and at least one positively charged polymeric conjugate, the link between the nucleic acid and the polymeric conjugate being electrostatic in nature, the polymeric conjugate containing a polymer formed from monomer components having free NH.sub.3.sup.+ functions of the aforementioned components and being as follows:--the free NH.sub.3.sup.+ functions from the aforementioned components are substituted in a ratio of at least 10%, advantageously from 45% to 70%, particularly 60%, by noncharged residues leading to a reduction of positive charges in comparison to the same nonsubstituted polymeric conjugate, facilitating the release of nucleic acid by the dissociation of the complex,--the aforementioned residues possess in addition the following properties:.fwdarw.they contain at least one hydroxyl group,.fwdarw.they do not correspond to a recognition signal recognized by a cellular membrane receptor,--the free NH.sub.3.sup.+ functions from the above mentioned components and/or the hydroxyl groups of the above mentioned residues are also able to be substituted by at least one molecule which constitutes a recognition signal recognized by a cellular membrane receptor, under the condition that the polymeric conjugate contains at least 30% free NH.sub.3.sup.+ functions.
摘要翻译：本发明涉及至少一个带负电荷的核酸和至少一个带正电荷的聚合物缀合物之间的复合物，核酸和聚合物缀合物之间的连接本质上是静电的，所述聚合物缀合物含有由具有游离NH 3+的单体组分形成的聚合物，上述组分的功能如下： - 上述组分的游离NH 3+官能团以至少10％，有利地为45％至70％，特别是60％的比例被非电荷残基取代，导致降低与相同的非取代的聚合物缀合物相比，正电荷有利于通过络合物的解离释放核酸，上述残基另外具有以下性质： - >它们含有至少一个羟基， - >它们不对应于由细胞膜受体识别的识别信号， - 来自a的游离NH 3+功能所述提及的组分和/或上述残基的羟基也能够被至少一种构成由细胞膜受体识别的识别信号的分子取代，条件是聚合物缀合物含有至少30％的游离 NH3 +功能。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式